Zobrazeno 1 - 10
of 38
pro vyhledávání: '"R L, Priore"'
Autor:
R. H. Whitham, D. S. Dougherty, P. M. Pullicino, David M. Bartoszak, Michael E. Coats, J. S. Fischer, Jack H. Simon, C. M. Brownscheidle, L. D. Jacobs, Richard A. Rudick, B. Weistock-Guttman, N. A. Simonian, B. J. Scherokman, J. R. Richert, C. V. Granger, Robert M. Herndon, Michele Mass, D. L. Cookfair, Andres M. Salazar, R. L. Priore, J. J. Alam, R. P. Kinkel, Dennis Bourdette, F. E. Munschauer, Jonathan Braiman, S. L. Cohan, Donald E. Goodkin, M. K. Campion
Publikováno v:
Neurology. 49:358-363
Background and Objective: A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-la (IFNβ-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29bb515d0eef4fe10f80d9ae4105c35
https://doi.org/10.1212/wnl.49.2.358
https://doi.org/10.1212/wnl.49.2.358
Autor:
R A, Rudick, D E, Goodkin, L D, Jacobs, D L, Cookfair, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, C V, Granger, J H, Simon, J J, Alam, N A, Simonian, M K, Campion, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, P M, Pullicino, B J, Scherokman, B, Weistock-Guttman, R H, Whitham
Publikováno v:
Neurology. 57(12 Suppl 5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d81f0874df8696917c43e6fb38fbf53a
https://pubmed.ncbi.nlm.nih.gov/11902591
https://pubmed.ncbi.nlm.nih.gov/11902591
Autor:
J S, Fischer, R L, Priore, L D, Jacobs, D L, Cookfair, R A, Rudick, R M, Herndon, J R, Richert, A M, Salazar, D E, Goodkin, C V, Granger, J H, Simon, J H, Grafman, M D, Lezak, K M, O'Reilly Hovey, K K, Perkins, D, Barilla-Clark, M, Schacter, D W, Shucard, A L, Davidson, K E, Wende, D N, Bourdette, M F, Kooijmans-Coutinho
Publikováno v:
Annals of neurology. 48(6)
Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon beta-1a (IFNbeta-1a, 30 microg administered intramuscularly o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c5be9df58cfd5af043e1b13ba008269f
https://pubmed.ncbi.nlm.nih.gov/11117545
https://pubmed.ncbi.nlm.nih.gov/11117545
Autor:
R A, Rudick, D L, Cookfair, N A, Simonian, R M, Ransohoff, J R, Richert, L D, Jacobs, R M, Herndon, A M, Salazar, J S, Fischer, C V, Granger, D E, Goodkin, J H, Simon, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munchsauer, K, O'Reilly, R L, Priore, R H, Whitham
Publikováno v:
Journal of neuroimmunology. 93(1-2)
This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III clinical trial of IFNbeta-Studies supported by the National Multiple Sclerosis Society (gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13f8a411328cfa8b2d962e4b41cd40a6
https://pubmed.ncbi.nlm.nih.gov/10378864
https://pubmed.ncbi.nlm.nih.gov/10378864
Autor:
D E, Goodkin, R L, Priore, K E, Wende, M, Campion, D N, Bourdette, R M, Herndon, J S, Fischer, L D, Jacobs, D L, Cookfair, R A, Rudick, J R, Richert, A M, Salazar, C V, Granger, J H, Simon, J J, Alam, D M, Bartoszak, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R H, Whitham
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 4(6)
We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4cbec0bcb408388be21c121001352b2e
https://pubmed.ncbi.nlm.nih.gov/9987756
https://pubmed.ncbi.nlm.nih.gov/9987756
Publikováno v:
The American journal of sports medicine. 26(2)
In a sports medicine center, we prospectively evaluated the Ottawa Ankle Rules over 1 year for their ability to identify clinically significant ankle and midfoot fractures and to reduce the need for radiography. We also developed a modification to im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7f4b5ea840b52a8d0430f666b9bce723
https://pubmed.ncbi.nlm.nih.gov/9548106
https://pubmed.ncbi.nlm.nih.gov/9548106
Autor:
R A, Rudick, D E, Goodkin, L D, Jacobs, D L, Cookfair, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, C V, Granger, J H, Simon, J J, Alam, N A, Simonian, M K, Campion, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, R H, Whitham
Publikováno v:
Neurology. 49(2)
A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outcome was time from study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7783e2a2501640a2e27e5006f5d19ba
https://pubmed.ncbi.nlm.nih.gov/9270562
https://pubmed.ncbi.nlm.nih.gov/9270562
Autor:
J L, Ambrus, S, Chadha, D, Novick, M, Rubinstein, B, Gopalakrishnan, Z, Bernstein, R L, Priore, K C, Chadha
Publikováno v:
Research communications in molecular pathology and pharmacology. 96(3)
We have earlier reported that patients suffering from acquired immuno-deficiency syndrome (AIDS), systemic lupus erythematosus (SLE) with vasculitis, Wegner granulomatosis and certain types of late stage cancer have interferon inhibitory activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::180e5ce52b1a9ea74cdc550424f2ade8
https://pubmed.ncbi.nlm.nih.gov/9261885
https://pubmed.ncbi.nlm.nih.gov/9261885
Autor:
L D, Jacobs, D L, Cookfair, R A, Rudick, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, D E, Goodkin, C V, Granger, J H, Simon, J J, Alam, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, P M, Pullicino, B J, Scherokman, R H, Whitham
Publikováno v:
Annals of neurology. 39(3)
The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f379bfe0a277fa6e5b29536620ab80b5
https://pubmed.ncbi.nlm.nih.gov/9403493
https://pubmed.ncbi.nlm.nih.gov/9403493
Publikováno v:
Journal of Biological Chemistry. 254:1211-1216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f30cdf6b26b701d5859069075f895443
https://doi.org/10.1016/s0021-9258(17)34189-3
https://doi.org/10.1016/s0021-9258(17)34189-3